Introduction
============

Chronic lymphocytic leukemia (CLL) is generally known as a heterogeneous disease with different clinical features and disease prognosis. A number of biological features, including immunoglobulin heavy variable (IGHV) mutational status, zeta-chain-associated protein kinase 70, CD38 expression and cytogenetic abnormalities, including myeloid differentiation primary response 88 (*MYD88*) mutations in leukemic lymphocytes have been reported to be correlated with clinical outcome ([@b1-ol-0-0-10342]--[@b4-ol-0-0-10342]). MYD88 protein is encoded by the *MYD88* gene, which is located on chromosome 3 p22.2. The *MYD88* mutation has been found in various lymphoproliferative disorders, including Waldenström macroglobulinemia, diffuse large B-cell lymphoma and CLL ([@b5-ol-0-0-10342]--[@b7-ol-0-0-10342]). In a number of studies, researchers have observed that patients with *MYD88* mutations exhibit high expression levels of genes in the NF-κB signaling pathway, in addition to an early appearance of CLL ([@b3-ol-0-0-10342],[@b8-ol-0-0-10342],[@b9-ol-0-0-10342]). *MYD88* gene mutations have been shown to be correlated with the drug resistance and prognosis of CLL ([@b3-ol-0-0-10342]). In recent studies, *MYD88* mutation rates of 2--5% in patients with CLL have been reported ([@b10-ol-0-0-10342],[@b11-ol-0-0-10342]). The p.L265P mutation in the *MYD88* gene is the main somatic mutation in CLL accounting for 84% worldwide ([@b12-ol-0-0-10342]). The p.L265P substitution at exon 5 in *MYD88* has been indicated to activate the NF-κB pathway, thereby conferring a proliferative and survival advantage to the mutant cells ([@b11-ol-0-0-10342]--[@b14-ol-0-0-10342]). However, other studies have reported that p.L265P in *MYD88* serves as a favourable prognostic marker in patients with CLL ([@b8-ol-0-0-10342],[@b10-ol-0-0-10342]). The aim of the present study was to find an effective and convenient method for detecting the *MYD88* p.L265P mutation.

High resolution melting (HRM) analysis is a technique first established in 2003, that has been developed for the high-throughput and convenient genotyping of individual polymorphic loci ([@b15-ol-0-0-10342]). The key to this technology is the use of saturating fluorescence dyes, which intercalate into double-stranded DNA during amplification of the DNA without inhibiting the PCR reaction. The dye fluoresces strongly when intercalated into the double-stranded DNA, but as the temperature increases during the HRM analysis, the DNA melts and the dye is release without fluorescence. The changes in fluorescence are sequence specific and can be recorded and analyzed by the designed program ([@b16-ol-0-0-10342],[@b17-ol-0-0-10342]).

The aim of the present study was to develop a RT-qPCR analysis method utilizing high-resolution melting technology for the accurate and convenient detection of the *MYD88* p.L265P mutation in patients with CLL. The mutations were simultaneously confirmed by direct sequencing analysis, and the sensitivities of the two methods were compared.

Materials and methods
=====================

### Clinical specimens

A total of 129 patients, 78 male and 51 female patients, diagnosed with CLL between October 2015 and October 2017 at the First Affiliated Hospital of Soochow University (Suzhou, China) were included in the present study. The mean age of the population was 62.19 years. Patients were newly diagnosed without any prior therapy. Bone marrow samples were collected from the patients (ethics approval no. 709.2). Written informed consent was obtained from all patients. The study was approved by the Ethics Committee of the First Affiliated Hospital of Soochow University.

### Genomic (g)DNA extraction

Lymphocyte cell separation and density gradient centrifugation were used to collect monocytes from the bone marrow samples of the patients with CLL using Histopaque-1077 (Sigma-Aldrich; Merck KGaA; cat no. 10771). Centrifugation speed was 400 × g for 20 min at room temperature. gDNA was extracted from these cells using a gDNA isolation kit (Omega BIO-TEK; cat no. M6399-00), according to the manufacturer\'s protocols. Each DNA sample was quantified using a NanoDrop ND-1000 fluorospectrometer (Thermo Fisher Scientific, Inc.), and samples with a A260/280 value between 1.8 and 2.0 were retained.

### Examination of the IGHV mutations status

The IGHV mutation status was detected using an IGHV somatic hypermutation assay v2.0 kit (Invivoscribe), according to the manufacturer\'s protocols. The PCR products were sequenced and considered as unmutated if the homology with the closest germline sequence showed \>98%.

### Construction of a plasmid containing wild-type MYD88 gene

The TA cloning kit (Invitrogen; Thermo Fisher Scientific; cat no. C45-0046) was used to prepare a PCR product containing exon 5 of wild-type *MYD88* gene in a plasmid vector. Primer sequences were as follows: Forward, 5′-GTGAATGTGTGCCAGGGGTA-3′ and reverse, 5′-GGTTGGTGTAGTCGCAGACA-3′. PCR was performed in a 50 µl reaction volume, according to the kit protocol. PCR thermocycling conditions were as follows: 95°C for 30 sec; 40 cycles of 95°C for 30 sec, 55°C for 60 sec and 72°C for 45 sec; and then stopped at 10°C. Gel purification of the PCR fragment was then performed (gel extraction kit; Omega BIO-TEK; cat no. D2500-01). The clone was ligated into vector pCR 2.1 from the TA cloning kit, according to the manufacturer\'s protocol, and the construct was then transformed into competent *E. coli* cells. The final plasmid pCMV-MYD88-TA, comprising the wild-type exon 5 of *MYD88*, was verified by sequencing and stored at −20°C.

### Site-directed mutagenesis

Site-directed mutagenesis was performed using a Muta-direct™ Site Directed Mutation kit (cat. no., SDM-125; Beijing SBS Genetech Co., Ltd.) according to the manufacturer\'s protocol, in order to obtain a plasmid with a p.L265P mutant of *MYD88*. The following primers were designed as instructed by the kit, and synthesized by Invitrogen (Thermo Fisher Scientific, Inc.): Forward, 5′-CCATCAGAAGCGACCGATCCCCATCAAGTA-3′ and reverse, 5′-TACTTGATGGGGATCGGTCGCTTCTGATGG-3′. PCR was conducted according to the kit protocol. The PCR thermocycling conditions were as follows: 95°C for 30 sec; 40 cycles of 95°C for 30 sec, 55°C for 60 sec and 72°C for 45 sec; and stopped at 10°C. The PCR product was treated with 1 µl Mutazyme™ from the kit at 37°C for 1 h. Competent *E. coli* DH5α cells were then transformed with the treated PCR product. Consequently, the final plasmid pCMV-MYD88-L265P-Mu containing the mutated *MYD88* was verified by sequencing and stored at −20°C.

### HRM analysis

HRM PCR primers were designed according to the genomic reference sequences of *MYD88* (NG_016964.1). Forward, 5′-GACTGGGCTTGTCCCACC-3′ and reverse, 5′-CGCAGACAGTGATGAACCTC-3′. The p.L265P mutation is a T to C nucleotide change (c.794T\>C) in exon 5 of the *MYD88* gene and results in an amino acid change from leucine (CTG) to proline (CCG) ([@b7-ol-0-0-10342]).

Fast Evagreen^®^ qPCR Master mix (Biotium) was used with a LightCycler 480 instrument (Roche Diagnostics) for the HRM assay. The final reaction mixture contained: 5 µl 2X Fast Evagreen^®^ qPCR Master mix, 1 µl 40 nM forward primer and 40 nM reverse primer, 75 ng gDNA, and PCR water to a total of 20 µl. The cycling and melting conditions were as follows: 94°C for 5 min; 50 cycles at 94°C for 30 sec, 60°C for 30 sec and 72°C for 45 sec. HRM conditions were as follows: 95°C for 1 min, 40°C for 1 min, 65°C for 1 sec, with a continuous increase in temperature from 65 to 95°C at a rate of 0.02°C/sec with 25 signal acquisitions per degree; and cooling at 40°C for 30 sec. The melting curve analysis was subsequently performed using LightCycler 480 Gene Scanning 1.5 software (Roche Diagnostics). Each sample analysis was repeated twice.

### Direct sequencing

Genomic sequence screening of *MYD88* (NG_016964.1) in CLL was accomplished through direct sequencing. Forward and reverse primers used in direct sequencing were the same of those in the aforementioned HRM reaction. The PCR mixture contained 2 µl 10X PCR buffer, 0.5 µl 10 nM dNTPs, 0.5 µl 20 pmol/µl forward primer and reverse primer, 0.1 µl TaqDNA polymerase (Invitrogen; Thermo Fisher Scientific, Inc.), 1.2 µl 1.5 mM Mg^2+^, 1 ng genomic DNA, and PCR water to a total of 20 µl. The cycling and melting conditions were as follows: 94°C for 5 min; and 40 cycles of 94°C for 30 sec, 60°C for 30 sec and 72°C for 45 sec. Final PCR products were qualified and bi-directionally sequenced using an ABI 3730 DNA Analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc.). All the nucleotide changes detected by bi-directional sequencing were inspected using the Sanger COSMIC database (web address: <http://cancer.sanger.ac.uk>).

### Sensitivity determination

The pCMV-MYD88-L265P-Mu plasmid (positive control) was serially diluted with the TA clone plasmid (negative control) in order to evaluate the sensitivity of the HRM assay and direct sequencing assay. Dilutions comprising 100, 50, 20, 10, 5, 1 and 0% TA clone plasmid were prepared.

Results
=======

### Establishment of site-directed gene mutagenesis

Since no validated cell line containing *MYD88* p.L265P exists, the plasmid pCMV-MYD88-L265P-Mu was constructed as a positive control using a Muta-direct Site Directed Mutation kit, according to the manufacturer\'s protocol. The plasmid pCMV-MYD88-L265P-Mu that was constructed was further verified by direct sequencing. A mutation at position 794 (794T\>C) was indicated ([Fig. 1](#f1-ol-0-0-10342){ref-type="fig"}).

### MYD88 p.L265P mutation detection by HRM assay

For HRM analysis, the optimal temperature and suitable primer concentration were selected to obtain PCR products with efficient amplification and a satisfactory melting profile. LightCycler 480 Gene Scanning 1.5 software was used to analyze the normalized and difference melting curves for the mutation status evaluation of patients. The results revealed that 4.65% (6/129) of the patients had melting curves and plots that differed from the others. HRM analysis of *MYD88* exon 5 revealed a point mutation at position 794 that could be identified by an elevated melting curve that differed from that of the negative control ([Fig. 2A and B](#f2-ol-0-0-10342){ref-type="fig"}). Basic characteristics of the patients with CLL, according to *MYD88* p.L265P mutations, are presented in [Table I](#tI-ol-0-0-10342){ref-type="table"}. In the analysis of basic characteristics of patients with CLL, IGHV mutations were found in all patients with *MYD88* p.L265P mutations. Patients with CLL with *MYD88* p.L265P mutations were younger at diagnosis (mean age is lower compared with the wild-type ones).

### Screening for MYD88 p.L265P mutations by direct sequencing

All 129 samples analyzed by the HRM assay were further analyzed by direct sequencing. A total of 6 (4.65%) patients were found have a mutation at position 794 (794T\>C) for the *MYD88* gene. The results of the HRM assay and direct sequencing were consistent ([Fig. 2C](#f2-ol-0-0-10342){ref-type="fig"}).

### Sensitivity evaluation by HRM assay and direct sequencing

The obtained pCMV-MYD88-L265P-Mu plasmid was used as a positive control for evaluation of the sensitivity and accuracy of the HRM assay and direct sequencing. The TA clone plasmid was used as a negative control. The negative control was used at serial dilutions of 100, 50, 20, 10, 5, 1 and 0% to evaluate the relative sensitivities of the two methods. [Fig. 3](#f3-ol-0-0-10342){ref-type="fig"} shows normalized and shifted melting curves, and normalized and temperature-shifted difference plots of the HRM data. The melting curve obtained using 1% mutated template clearly differed from the negative template. However, the mutation was detectable by direct sequencing when the mutant frequency was \>10% ([Fig. 4](#f4-ol-0-0-10342){ref-type="fig"}). These results indicate that the HRM analytical method for detection of the *MYD88* p.L265P mutation has higher sensitivity than direct sequencing.

Discussion
==========

The development of personalized and targeted therapies has created an increased demand for the molecular profiling of cancers in order to provide more appropriate treatment ([@b18-ol-0-0-10342]). CLL is the second most common type of leukemia in adults in the western world. It is characterized by the proliferation and progressive accumulation of mature clonal B lymphocytes in the bone marrow, lymphoid tissues and blood ([@b19-ol-0-0-10342],[@b20-ol-0-0-10342]). In previous studies, numerous molecular indices have been shown to be informative in predicting the disease course and treatment direction, including *TP53, BIRC3, SF3B1, NOTCH1* and *MYD88* ([@b21-ol-0-0-10342]--[@b23-ol-0-0-10342]). These genes, with the exception of *MYD88*, have been associated with a shorter time to treatment, as well as overall survival ([@b24-ol-0-0-10342]). MYD88 is a cytoplasmic soluble protein of the interleukin-1 receptor/Toll-like receptor (TLR) pathway ([@b25-ol-0-0-10342]). TLRs in B cells may act as a trigger for a non-specific immune response following the recognition of certain molecular patterns, and CLL cells express a pattern of TLRs similar to that of normal memory B cells ([@b26-ol-0-0-10342]). The stimulation of TLRs activates the NF-κB and mitogen-activated protein kinase signaling pathways and protects CLL cells from spontaneous apoptosis ([@b8-ol-0-0-10342]). Therefore, TLR activation may be relevant to the pathogenesis of CLL. It has been reported that the predominant mutation of CLL, which is a p.L265P substitution within exon 5 in *MYD88*, may lead to NF-κB stimulation and thereby provide a proliferation and survival advantage for CLL mutant cells. *MYD88* mutations have been reported in 2--5% of CLL cases, with the majority of cases carrying the p.L265P substitution ([@b20-ol-0-0-10342],[@b21-ol-0-0-10342]).

An HRM assay was conducted in the present study as a potentially reliable, rapid and low-cost genotyping assay for the detection of the *MYD88* p.L256P mutation in CLL. To the best of our knowledge, this is the first study reporting *MYD88* p.L256P mutation screening in the bone marrow samples of Chinese patients with CLL. A relatively low frequency of the *MYD88* hotspot mutation (4.65%) was identified. Due to the low number of CLL cases with *MYD88* mutations, it was not possible to detect an association with clinical outcome.

The HRM analysis of amplicons is based on fluorescence measurements during the melting of double-strand DNA in the presence of saturating DNA-binding dyes, which are used to create a melting curve, derivative plot or difference plot for analysis ([@b27-ol-0-0-10342]). The present study used the HRM assay to generate specific melting profiles, which distinguished between wild-type and mutated variants due to differences in nucleosides. The normalized and shifted melting curves of 6/129 samples were clearly different from those of samples from the other patients.

In order to confirm the reliability of the HRM analysis, all the mutated samples were simultaneously analyzed by direct sequencing. Direct sequencing identified 6 samples that harbored the *MYD88* p.L256P mutation, and was consistent with the results of the HRM assay. The mutation frequency was similar to that found in previous studies using other assay methods ([@b28-ol-0-0-10342]--[@b30-ol-0-0-10342]). The HRM analysis in the present study was highly sensitive, and was able to detect a mutation rate of 1%. This indicates that the sensitivity of the HRM analysis was higher compared with that of direct sequencing analysis, with a sensitivity of 10% ([@b30-ol-0-0-10342],[@b31-ol-0-0-10342]).

The protein truncation test (PTT), DNA sequencing, PCR-single-strand conformation polymorphism (PCR-SSCP), conformation sensitive gel electrophoresis (CSGE), and HRM methods are often used to detect gene mutations. PTT uses radioactive labels for protein detection ([@b32-ol-0-0-10342]). PCR-SSCP is simple to perform, but is time-consuming and has low sensitivity for the detection of genetic variations ([@b33-ol-0-0-10342]). CSGE has high efficiency and relatively high sensitivity, but is also time-consuming and expensive ([@b34-ol-0-0-10342]). Direct sequencing is considered the gold standard, and can identify any mutation in a DNA sequence ([@b35-ol-0-0-10342]). However, its high cost, limited sensitivity and extensive testing time limit its application. Therefore, HRM analysis provides an alternative technique for the detection of mutations. The PCR amplification and subsequent analysis conducted during the HRM assay are performed in a single closed tube, and so this method is more convenient and faster than other scanning methods ([@b12-ol-0-0-10342],[@b29-ol-0-0-10342]). The use of a closed-tube in the HRM analysis minimizes the risk of contamination of the post-PCR product during scanning, while also decreasing the processing time. Notably, in the present study, the quantity of gDNA required was only 75 ng, and the whole testing procedure took only 2 h.

The present study suggests the value of HRM analysis as a screening tool for mutations. However, it also has certain limitations ([@b36-ol-0-0-10342]). Firstly, the presence of undiscovered polymorphisms in the genes may interfere with genotyping. Therefore, this study deliberately designed amplicon lengths of only 149 bp, because the wild-type and heterozygote curves become too small to distinguish as the amplicon length increased. Secondly, the HRM assay cannot detect mutations containing an entire exon or deletions of entire genes and exons. Thirdly, the HRM method requires that the DNA to be analyzed is of good quality. Therefore, the present study used bone marrow samples to obtain gDNA with good quality. In addition, the sample size in the present study was small, and larger studies are required to further validate the results.

In conclusion, HRM analysis was demonstrated to be a feasible method for the clinical detection of the *MYD88* p.L256P mutation. It is more sensitive than DNA sequencing, cost-efficient and has a reduced processing time. To the best of our knowledge, this is the first time that the HRM assays have been used in the detection of *MYD88* mutation in patients with CLL. This study indicates that HRM analysis may be useful in a clinical setting for the screening of *MYD88* mutations during the preliminary diagnosis or clinical course of CLL.
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![Sequencing result of two plasmids. (A) Sequence of the WT *MYD88* plasmid. There is no mutation at position 794 (arrow). (B) Sequence of the mutant *MYD88* plasmid pCMV-MYD88-L265P-Mu. There is a mutation at position 794 T\>C (arrow). *MYD88*, myeloid differentiation primary response 88; WT, wild-type; Mu, mutated.](ol-18-01-0814-g00){#f1-ol-0-0-10342}

###### 

Melting curves, difference plots and sequence traces for the *MYD88* p.L265P mutation. (A) Normalized and shifted melting curves of *MYD88* p.L265P indicate that the HRM assay was able to distinguish the T\>C mutation at position 794 from WT. (B) Normalized and temperature-shifted difference plots indicate that the HRM assay distinguished the T\>C mutation at position 794 from WT. (C) Sequencing chromatograms confirmed the T\>C mutation at position 794 (arrow). *MYD88*, myeloid differentiation primary response 88; HRM, high resolution melting assay; WT, wild-type; CLL, chronic lymphocytic leukemia.
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![Validation and sensitivity testing for the HRM assay. The TA clone plasmid (WT) was used as a negative control. Various dilutions of WT were used to generate (A) normalized and shifted melting curves and (B) normalized and temperature-shifted difference plots of the HRM data. The melting curve for 1% WT template clearly differed from the positive template. HRM, high resolution melting assay; WT, wild-type; MU, mutated.](ol-18-01-0814-g03){#f3-ol-0-0-10342}

![Validation and sensitivity testing for direct sequencing. Direct sequencing results of *MYD88* p.L265P mutations at serial dilutions (100, 50, 20, 10, 5, 1 and 0%) with negative control. The sensitivity for direct sequencing was indicated to be 10%. Arrows indicate the mutation site. *MYD88*, myeloid differentiation primary response 88; WT, wild-type; MU, mutated.](ol-18-01-0814-g04){#f4-ol-0-0-10342}

###### 

Characteristics of patients with CLL according to *MYD88* p.L265P mutation status.

  Characteristics       Value    *MYD88* wild type (n=123)   *MYD88* p.L256P (n=6)
  --------------------- -------- --------------------------- -----------------------
  Mean age, years       62.19    62.34                       56.00
  Sex (male/female)     78/51    72/51                       6/0
  IGHV mutated, (n/N)   12/129   0/123                       6/6

CLL, chronic lymphocytic leukemia; MYD88, myeloid differentiation primary response 88; IGHV, immunoglobulin heavy variable. n, the number of patients with *MYD88* wild-type and *MYD88* p.L256P; N, the total number of patients with CLL.
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